Biogen’s Alzheimer’s drug is unlikely to win E.U. approval.

Biogen’s Alzheimer’s Drug Is Unlikely To Win E.u. Approval.

The New York Times – by Rebecca Robbins

The drug maker Biogen said on Wednesday that a panel of drug reviewers in the European Union had indicated that its new Alzheimer’s drug was unlikely to be approved there, the latest setback for a medication that has been mired in controversy since it was in approved in the United States in June.

Read the whole story on nytimes.com

Report

What do you think?

1k Points
Upvote Downvote

Leave a Reply

Your email address will not be published.

How Mets Drove Noah Syndergaard Away In Final Days With Team: Sherman

How Mets drove Noah Syndergaard away in final days with team: Sherman

Biden Asks Ftc To Examine Oil, Gas Companies’ Role In High Gasoline Prices

Biden Asks FTC to Examine Oil, Gas Companies’ Role in High Gasoline Prices